The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear. METHODS: (stage 1 or 2 CKD). Patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary outcome, assessed in a time-to-event analysis, was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The first secondary outcome was a composite of kidney failure, a sustained decrease from baseline of at least 40% in the eGFR, or death from renal causes. Safety was assessed as investigator-reported adverse events. RESULTS: A total of 7437 patients underwent randomization. Among the patients included in the analysis, during a median follow-up of 3.4 years, a primary outcome event occurred in 458 of 3686 patients (12.4%) in the finerenone group and in 519 of 3666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P = 0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90). The secondary composite outcome occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 1.01). The overall frequency of adverse events did not differ substantially between groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%). CONCLUSIONS: Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in kidney failure: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) outcome trial (460) demonstrates a significant relationship between reduction in moderately increased albuminuria and reduction in cardiovascular risk.”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [460]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Discontinuation of trial regimen was higher among those on fi nerenone than placebo (1.2% vs. 0.4%).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with T2D and albuminuria are known to be at high risk of CKD progression and cardiovascular events, and the FIDELIO-DKD and FIGARO-DKD trials demonstrated that fi nerenone reduced these events (particularly CKD progression and heart failure) among such patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pooled analysis of two complementary trials comprising 13 026 patients with a broad spectrum of CKD and type 2 diabetes, all treated with an optimized dose of an ACEi or ARB,7 , 10 provides robust evidence of both cardiovascular and kidney protection with finerenone vs. placebo.”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People with type 2 diabetes and CKD should be considered for treatment with finerenone to reduce cardiovascular outcomes and the risk of CKD progression (239–242).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finerenone was investigated in two complementary phase 3 studies of patients with T2D, kidney disease (defined primarily as ACR ≥30 mg/g), and potassium <4.8 mmol/L and is the only ns-MRA approved in the world for slowing CKD progression and reducing cardiovascular events.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in ESKD: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“There was a 13% lower risk of the primary cardiovascular composite outcome, which included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“The secondary composite kidney outcome, which included kidney failure, sustained decrease from baseline of at least 40% in eGFR, or death from kidney causes, was not signi fi cantly different between fi nerenone and placebo (HR 0.87, 95% CI 0.76 -1.01).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“On average, there was only a small reduction in systolic blood pressure (3 mm Hg) with fi nerenone compared to placebo, and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“and fi nerenone reduced the risk of kidney and cardiovascular outcomes in 2 pivotal outcome trials.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the primary cardiovascular composite outcome risk in a broader patient population than studied in FIDELIO-DKD (patients with stage 2–4 CKD and moderately increased albuminuria, or stage 1–2 CKD with severely increased albuminuria).7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The FIDELIO-DKD trial was designed to detect a treatment effect of finerenone on kidney failure endpoints, whereas the FIGARO-DKD trial aimed to detect an effect on a cardiovascular composite primary endpoint.7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76-0.98];P = 0.03) in people with type 2 diabetes and CKD (248).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56-0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56–0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76–0.98]; P = 0.03) in people with type 2 diabetes and CKD (240).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In summary, FIDELIO-DKD and FIGARO-DKD demonstrated cardiovascular and kidney benefits for finerenone among people with T2D who were treated with standard of care (including an RAS inhibitor at maximally tolerated doses and good control of glycemia and BP) who were at high residual risk, based largely on albuminuria (ACR ≥30 mg/g).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Physical activity and aerobic exercise guidelines are similar in persons with T2D independent of lean vs overweight/obese BMI.431,674,727,728”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [431]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, the updated evidence review identifi ed 27 RCTs on MRA, with 5 RCTs comparing nonsteroidal MRA to placebo and/or standard of care.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredIn the citing paper
“According to two large randomized placebo-controlled trials targeted at T2DM and CKD patients, finerenone has been demonstrated to significantly reduce the occurrences of composite renal outcome”
In the citing paper
“and composite cardiovascular outcome (defined as a composite of nonfatal MI, nonfatal stroke, death from cardiovascular causes, or hospitalization for heart failure [HHF]), regardless of patients with or without established cardiovascular disease [16, 17].”
In the citing paper
“Even more recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone has been shown to confer both cardiovascular and kidney protection in patients with T2D and CKD, in both a dedicated kidney outcome trial and a dedicated cardiovascular outcome trial [22,23].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [23]
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the composite cardiovascular outcome, which was the primary outcome of the trial (HR: 0.87, 95% CI: 0.76-0.98).26”
In the citing paper
“FIDELIO-DKD and FIGARO-DKD each enrolled people with T2D treated with the maximum-tolerated dose of RASi who had residual albuminuria (ACR $30 mg/g [$3 mg/mmol]) and a nonelevated serum potassium (<4.8 mEq/l at screening).”
In the citing paper
“This recommendation is based on the high-quality evidence from FIDELIO-DKD and FIGARO-DKD (Grade A, summarized above) that finerenone slows progression of CKD and reduces risks of cardiovascular events in this population.25,26”
In the citing paper
“Two large clinical trials (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease [FIDELIO-DKD] 25 and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease [FIGARO-DKD] 26 ) and a pre-specified individual-level combined analysis of these 2 trials (The FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD”
In the citing paper
“To mitigate hyperkalemia risk, the FIDELIO-DKD and FIGARO-DKD trials restricted eligibility to patients with non-elevated serum potassium concentration (after maximizing RASi) and implemented a standardized potassiummonitoring protocol.”
In the citing paper
“The HR of the primary outcome of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization from heart failure was reduced by 13% in patients treated with fi nerenone.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationChronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationCoresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Cited by
Sorted by citations
Items 801–900 of 1,000
Chung, S. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.6.270 · Cited by 6
Du, Y., Gui, C., Gu, L., Chen, Y., & Liu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1237583 · Cited by 6
Non-cardiac comorbidities in heart failure: an update on diagnostic and management strategies
Kodur, N., & Tang, W. H. W. (2024) · Minerva Medica · doi:10.23736/s0026-4806.24.09070-0 · Cited by 6
Liuzzo, G., & Volpe, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab725 · Cited by 6
Салухов, В. В., Шамхалова, М. Ш., & Duganova, A. V. (2023) · Terapevticheskii arkhiv · doi:10.26442/00403660.2023.03.202152 · Cited by 6
Wu, Y., Gao, Y., Guo, X., Zhang, J., & Li, A. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70023 · Cited by 5
Wang, M., Wang, C., Zhao, M., Feng, Z., Li, Y., Li, L., Yao, S., Liu, H., & Xue, H. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104191 · Cited by 5
Carlino, I., Pirrotta, F., Gennari, L., & Palazzuoli, A. (2025) · Biomedicines · doi:10.3390/biomedicines13071693 · Cited by 5
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 7
Chen, A., & Wang, F. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02384-x · Cited by 5
Soe, K. K., & Selvarajah, D. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101149 · Cited by 5
Nugroho, P., Lydia, A., Soewondo, P., Suhardjono, S. S., Timan, I. S., Harimurti, K., & Ali, Z. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2577271 · Cited by 5
Han, M., Wang, J., Guo, S., Zhu, H., Zhao, L., Wu, Z., Wu, Y., Guo, J., Liao, J., & Tang, Z. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.070 · Cited by 5
Charting the future of cardiorenal medicine: a vision for integration, innovation, and impact
Kazory, A., Ronco, C., & Koratala, A. (2025) · Frontiers in Nephrology · doi:10.3389/fneph.2025.1719673 · Cited by 5
From RAAS blockade to regenerative medicine: evolving treatment strategies in Alport syndrome
Re, C. L., Kim, J., & Fornoni, A. (2025) · Pediatric Nephrology · doi:10.1007/s00467-025-07046-z · Cited by 5
Efficacy and Safety of Finerenone in Kidney Transplant Patients
Kahvecioğlu, S., Celik, H. T., Yalcinkaya, A. S., Ayar, Y., Aktaş, N., & Akarsu, Ö. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238296 · Cited by 5
Yu, Y., Shan, Y., Ding, A., & Qian, H. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117605 · Cited by 5
Gu, C., Li, X., Guo, X., Zhou, J., Kang, L., & Fang, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-27239-8 · Cited by 5
Wang, T.-Y., Zhang, L., Wang, H.-Y., & Jiang, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1725782 · Cited by 5
Ribeiro, V. M., Cavalcante, D. N., Celkevicius, H. E. T., Camacho, G. C. G., Neves, H. A. F., de Souza, K., Machado, R. H., Lopes, L. M., Donaldy, W., Bortolotto, L. A., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf246 · Cited by 6
Chen, S.-H., Tseng, Y., Huang, C., Yang, S., Fudim, M., Chuang, S., Sung, S., & Cheng, H.-M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70503 · Cited by 5
Hamatani, Y., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag030 · Cited by 5
Self-citationEmerging Medical Therapies for Primary Aldosteronism
Vibhatavata, P., & Turcu, A. F. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26229 · Cited by 5
Subclinical Primary Aldosteronism and eGFR Decline Over Time
Hundemer, G. L., Desbiens, L., Agharazii, M., Madore, F., Vaidya, A., Leung, A. A. C., Kline, G. A., Sood, M. M., Akbari, A., White, C., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001039 · Cited by 5
Quadruple therapy in heart failure: Why, when, and in whom?
PARASKEVAIDIS, I. A., Tsougos, E., & Kourek, C. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103352 · Cited by 5
Kubica, J., Kubica, A., Ratajczak, J. M., Gajda, R., Szarpak, Ł., & Navarese, E. P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093486 · Cited by 5
Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
Agarwal, R., Correa‐Rotter, R., Navaneethan, S. D., Heerspink, H. J. L., Weir, M. R., McGill, J. B., Mottl, A. K., Nangaku, M., Rosenstock, J., Rossing, P. R., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.27036 · Cited by 5
Self-citationManaging cardio-renal-metabolic risk in patients with type 2 diabetes: the role of finerenone
Filardi, T., Feraco, A., Ouvrard‐Pascaud, A., Rizzo, M., & Caprio, M. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108741 · Cited by 5
Black, J. E., Campbell, D. J. T., Ronksley, P. E., McBrien, K. A., & Williamson, T. S. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.001 · Cited by 5
Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone
Huang, Y., Gao, H., Lin, Y., Chen, X., Chen, M., & Chen, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2412218 · Cited by 5
Chen, J., Xue, J., Chen, J., Xie, T., Sui, X., Zhang, Y., Zhang, A., Xu, Y., & Chen, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1461754 · Cited by 5
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2025) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2025.161004 · Cited by 6
Fong, J. M. N., Sia, C., & See, K. C. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-012 · Cited by 5
Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index
Rossing, P. R., Birkenfeld, A. L., Fioretto, P., McGill, J. B., Anker, S. D., Pitt, B., Rohwedder, K., Scalise, A. V., Scott, C. A. B., Filippatos, G. S., et al. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000700 · Cited by 5
Self-citationAdverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
Yu, W., Luo, F., Rao, J., Lei, G., Wu, Q., Shen, W., Yang, P., & Li, P. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1601552 · Cited by 5
Prognosis After >50% Decline in eGFR in Heart Failure Patients
Zahir, D., Elmegaard, M., Garred, C. H., Nouhravesh, N., Fosbøl, E. L., Jhund, P. S., McMurray, J. J. V., Petrie, M. C., Køber, L., & Schou, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.027 · Cited by 5
Ambrosy, A. P., Daida, Y. G., Parikh, R., Tan, T. C., Howick, C. K., Alexeeff, S., Lo, J. C.-M., & Go, A. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.047 · Cited by 5
Motoki, H., Kuwahara, K., Uchida, H. A., Wada, J., Kario, K., Katsuya, T., Shimosawa, T., Tsujita, K., Suzuki, S., Suedomi, T., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02347-0 · Cited by 5
Fernández‐Fernández, B., Górriz, J. L., Cuenca, A. M. C., Fácila, L., González-Moro, J. M. R., Maraver, M. P., & Ortíz, A. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.027 · Cited by 5
Implementation of Cardiometabolic Centers and Training Programs
Taha, M. B., Rao, N., Vaduganathan, M., Cainzos‐Achirica, M., Nasir, K., & Patel, K. V. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01459-y · Cited by 5
The role of blood pressure management in stroke prevention: current status and future prospects
Narita, K., Hoshide, S., & Kario, K. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2137490 · Cited by 5
Ros, M. L., Aguilar-Gallardo, J. S., Shah, A., Narasimhan, B., & Aronow, W. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2138744 · Cited by 5
Was ist gesichert in der Therapie der chronischen Nierenerkrankung?
Greite, R., & Schmidt-Ott, K. M. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01422-9 · Cited by 5
Update on diabetic kidney disease
Rico-Fontalvo, J. E., Jiménez, L. C. V., Yánez, T. R., Daza-Arnedo, R., Raad-Sarabia, M., Hernández, J. D. M., Vargas, M. L., & Quintero, J. J. (2022) · Anales de la Facultad de Ciencias Médicas (Asunción) · doi:10.18004/anales/2022.055.03.86 · Cited by 5
Ahmad, M. I., Chen, L. Y., Singh, S., Luqman-Arafath, T. K., Kamel, H., & Soliman, E. Z. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.04.036 · Cited by 5
Rangaswami, J., & Mathew, R. O. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1512 · Cited by 5
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice
Tomasoni, D., Cannata, A. N., Adamo, M., & Metra, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14163 · Cited by 5
Fatemi, Y., Nikfar, M., Oladazimi, A., Zheng, J., Hoy, H. M., & Ali, H. B. (2024) · Healthcare · doi:10.3390/healthcare12121165 · Cited by 7
Arterial hypertension—clinical trials update 2024
Tokcan, M., Lauder, L., Götzinger, F., Böhm, M., & Mahfoud, F. (2024) · Hypertension Research · doi:10.1038/s41440-024-01900-7 · Cited by 7
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
Chronic Kidney Disease—Part 1: Evaluation & Risk Assessment in CKD, Methods to Delay CKD Progression
Larsen, D., Varanasi, L., & Estrella, M. M. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.07.004 · Cited by 5
Uchida, H. A., Wada, J., Motoki, H., Kuwahara, K., Kario, K., Katsuya, T., Shimosawa, T., Tsujita, K., Suzuki, S., Suedomi, T., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02259-z · Cited by 6
Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease
Raj, R. (2022) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000785 · Cited by 5
Ameliorating Cardiovascular Risk in Patients with Type 2 Diabetes
Motairek, I. K., & Al-Kindi, S. G. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.002 · Cited by 5
Renin Angiotensin Aldosterone System Blockers
Shibata, S., & Fujita, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00022-0 · Cited by 6
Shestakova, M. V., Dobronravov, V., As, A., Antsiferov, M. B., Batyushin, М. М., Bobkova, I. N., Galstyan, G. R., Demidova, T. Y., Klimontov, V. V., Mkrtumyan, A. M., et al. (2023) · Diabetes Mellitus · doi:10.14341/dm13020 · Cited by 5
Agarwal, R., & Rifkin, B. S. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.01.1049 · Cited by 5
Self-citationZaheen, M., Ferdous, F., Amarasekera, A. T., Petutschnigg, J., Edelmann, F., & Tan, T. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103598 · Cited by 4
Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold
Russo, E., Venturelli, E., Leoncini, G., Viazzi, F. C., & Pontremoli, R. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106627 · Cited by 4
Nadendla, R. R., Khairunnisa, K., Aziz, N., Pyne, C., Panigrahy, U. P., Wal, P., Kulkarni, M. H., & Rasheed, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291920240611063402 · Cited by 4
Finerenone and diabetic renal disease: a narrative review
Venkatesan, K., Cheryeth, M. M. J., Verghese, A. T., Mathews, A. M., Ravisankar, N., Unnikrishnan, P., Prakash, V., Harimohan, H., Haroon, N. N., James, S., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03945-7 · Cited by 4
Guan, Y., Yin, X., Wang, L., Diao, Z., Huang, H., & Wang, X. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s472412 · Cited by 4
Naami, R., Miller, D. M., Datla, S., Rahman, M. U., Al-Kindi, S. G., & Neeland, I. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000746 · Cited by 4
Lin, H., Gao, Q., Yin, Y., Peng, S., Dong, X., Zhao, Z., Huang, R., Tao, Y., Wen, S., Li, B., et al. (2025) · International Urology and Nephrology · doi:10.1007/s11255-025-04381-w · Cited by 4
Salinas, G. L. A., León, A. M., Cano, D. A., Esteban‐Fernández, A., Flórez, J. M. V., Díaz, S. D. P., Magaña, J. G., Delgado, G. D. L., Manzanares, R. G., Pérez, P. C., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15260 · Cited by 4
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT
Hobbs, R. F., McManus, R. J., Taylor, C. J., Jones, N. R., Rahman, J. K., Wolstenholme, J. L., Jones, L., Hirst, J. A., Mort, S., & Yu, L. (2025) · Health Technology Assessment · doi:10.3310/pyft6977 · Cited by 4
Haq, N., Uppal, P., Abedin, T., & Lala, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093213 · Cited by 4
Wang, J., Zheng, M., Yang, Y., Zhang, L., & Wulasihan, M. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15329 · Cited by 4
Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis
Sun, M., Xiao, F., Xue, C., Wang, L., & Dai, H. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.07.039 · Cited by 4
Chen, Q., Li, Y., Yang, S., He, H., Xie, Y., Wang, W., Wang, L., Gao, Y., Cai, L., Xiong, S., et al. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38389 · Cited by 4
Song, J. T., Kang, Y., Wang, L., Guo, Y., Jia, X., Dong, S., Li, Y., Wang, D., Gao, J., & Yang, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329965 · Cited by 4
Wang, X., & Su, D. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0408 · Cited by 4
Ahlers, M. J., John, S., Bhatia, H. S., Le, V. T., & Taub, P. R. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101265 · Cited by 4
Comprehensive management of chronic kidney disease in the old population
Franco, M. E. P., Puente-García, A., Perez-Belmonte, L. M., Pérez, N., Ellingson, S., & Tornero, F. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2551217 · Cited by 4
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 5
CHENG, A. Y. Y., Mottl, A. K., & MAGWIRE, M. L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01796-7 · Cited by 4
Hellenkamp, K., Kaebe, S., Valentová, M., von Haehling, S., Delistefani, F., Gollisch, K. S. C., Raddatz, D., Schäfer, A.-K. C., Koziolek, M. J., & Wallbach, M. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15424 · Cited by 5
Desai, N. R., Ahmad, T., & Wilson, F. P. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10564-5 · Cited by 4
The FLOW of Progress in Diabetic Kidney Disease: Semaglutide’s Role in Combination Therapy
Agarwal, R. (2025) · Diabetes Care · doi:10.2337/dci25-0088 · Cited by 4
Self-citationAlbuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes
Parveen, S., Malmborg, M. W., Arulmurugananthavadivel, A., Carlson, N., Andersson, C., Andersen, C. F., Jensen, J., Zahir, D., Elmegaard, M., Eroglu, T. E., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102254 · Cited by 4
Balakumar, P., Mulukuri, N. V. L. S., & Jagadeesh, G. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108945 · Cited by 5
Sconfienza, E., Mallart-Riancho, J., Gebara, N., Ferrão, D., Burrello, J., de Fréminville, J.-B., Deflorenne, E., Lorthioir, A., Azizi, M., & Amar, L. (2026) · Hypertension · doi:10.1161/hypertensionaha.125.24881 · Cited by 4
Kramer, H. J., & Bakris, G. L. (2026) · Journal of Internal Medicine · doi:10.1111/joim.70066 · Cited by 4
Self-citationEfficacy and Safety of the Kidney Function–Based Finerenone Dosing Strategy Used in FINEARTS-HF
Chimura, M., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Filippatos, G. S., Gajos, G., BRINKER, M. D., Amarante, F., Lay‐Flurrie, J., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.102938 · Cited by 4
Self-citationEfficacy and safety of finerenone in non-diabetic patients with IgA nephropathy
Wang, J., Tu, Y., Chen, Z., Guo, Z., Chen, J. X., Wu, B., Liu, Z., & Bao, H. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag023 · Cited by 4
Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF
Sauer, A. J., ter Maaten, J. M., & Savarese, G. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag056 · Cited by 4
Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease
Hu, S., Lee, K., He, C., & Fan, Y. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001053 · Cited by 4
Treatment of Primary Aldosteronism
Salle, S. P., Hundemer, G. L., Nehs, M. A., Barletta, J. A., & Vaidya, A. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.26238 · Cited by 4
Cherney, D. Z. I., Alicic, R. Z., & Bonaca, M. P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.01.010 · Cited by 4
Marshall, W. R., McDonnell, T., Green, D., Sinha, S., & Kalra, P. A. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106592 · Cited by 4
Jelwan, Y. A., Cao, T., Yao, Z., Burka, S., Erhabor, J., Berning, P., Dzaye, O. D. A., & Blaha, M. J. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.046837 · Cited by 4
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 4
Merker, L., Ebert, T., Guthoff, M., & Isermann, B. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1946-3783 · Cited by 4
Tommerdahl, K. L., Kula, A. J., & Bjornstad, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2203319 · Cited by 5
Wright, E. E., & Nicholas, S. B. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2350924 · Cited by 4
Correa-Rotter, R., Wheeler, D. C., & McEwan, P. C. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02950-6 · Cited by 4
The Increasing Problem of Resistant Hypertension: We’ll Manage till Help Comes!
Natale, F., Franzese, R., Luisi, E., Mollo, N., Marotta, L., Solimene, A., D’Elia, S., Golino, P., & Cimmino, G. (2024) · Medical Sciences · doi:10.3390/medsci12040053 · Cited by 7
Pharmacological management of heart failure: a patient-centred approach
Fibbi, G., Sato, R., Vatic, M., Genreith, F. P., & von Haehling, S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2418414 · Cited by 5
Mhaimeed, O., Dardari, Z., Khorsandi, M., Dzaye, O. D. A., Sharma, K., Nasir, K., Berman, D. S., Budoff, M. J., Shaw, L. J., Rumberger, J. A., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.437 · Cited by 4
Ten tips in lupus nephritis management
Teoh, S. T. Y., Yap, D. Y. H., & Chan, T. M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae376 · Cited by 4
Metadata
- Authors
- Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2252-2263
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3194763937
- Cited by
- 1,814
- References
- 32
- Citations by year
- 2026: 439 · 2025: 435 · 2024: 331 · 2023: 315 · 2022: 250 · 2021: 41
- FWCI
- 160.23
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- National University of Singapore (submittedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Bayer (ClinicalTrials.gov NCT02545049)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- mineralocorticoid receptor antagonists, type 2 diabetes, chronic kidney disease, cardiovascular events, heart failure hospitalization, albuminuria, renin-angiotensin system blockade, hyperkalemia, estimated glomerular filtration rate decline, renal failure, cardiorenal outcomes, FIDELIO-DKD
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Proportional Hazards Models, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
